Release issued 16th February 2009

Paris, February 16, 2009 – BioAlliance Pharma SA (Euronext Paris: BIO), the specialty pharmaceutical company focused on the treatment of opportunistic infections in cancer and AIDS, today announced the initiation of its European marketing application for ondansetron RapidFilm™, the fast-dissolving oral film strip formulation of ondansetron (which until now has been used in tablet form). This innovation is designed to prevent and treat nausea and vomiting induced by chemotherapy and radiotherapy. Ondansetron RapidFilm™ facilitates administration of the drug and improves efficacy and patient compliance.

The ondansetron film uses the RapidFilm™ drug delivery technology developed in joint venture by APR Applied Pharma Research s.a. (“APR”) of Switzerland and Labtec GmbH of Germany and enables novel oral dosing via a fast-dissolving film strip. The formulation is particularly suitable for patients with nausea or who have trouble swallowing.

In Europe, antiemetic drugs represent the main component of cancer supportive care and accounted for annual sales totaling over €400 million in the five largest markets in 20071. Ondansetron was the leading drug in its class in 2007, with around 800,000 prescriptions2.

BioAlliance Pharma estimates that the decentralized registration procedure (covering 16 European countries) should take between 9 and 12 months.

Dominique Costantini, BioAlliance Pharma's President and CEO, stated that "filing for marketing authorization in Europe via a decentralized procedure is a key milestone for our company on the road to commercialization of this new product. Our pharmaceutical, clinical and regulatory teams are fully committed to driving this application forward".

“RapidFilm™ technology aims to provide the quickest, easiest and most patient friendly way for the oral intake of drugs” said Paolo Galfetti CEO of APR ; “Ondansetron was an ideally candidate to maximize the both the patient and the market value of such feature and we believe BioAlliance is the best partner to bring this opportunity to a successful outcome in the market”

(28th July 2009) APR Applied Pharma Research SA. announces the signature of an exclusive licensing agreement with SciClone Pharmaceuticals Inc. for Ondansetron Rapidfilm™ for China and Vietnam

(24th June 2009) Abdi Ibrahim , APR and Labtec GmbH have entered into an exclusive licensing agreement under which Abdi Ibrahim has the exclusive rights to market Ondansetron Rapidfilm® in Turkey.

(22nd June 2009) FDA has approved Cambia™, Potassium Diclofenac Powder for Oral Solution for the treatment of acute migraine attacks with or without aura, originally developed by APR Applied Pharma Research SA (APR)

(17th November 2008) APR and Fidia have received IND approval from FDA for a new NSAID Matrix Patch product

(4th August 2008) APR Applied Pharma Research SA., together with its joint venture partner Labtec GmbH, announce the signature of an exclusive licensing agreement with BioAlliance Pharma SA. for Ondansetron RapidFilm